Perspectives on Oncolytic Salmonella in Cancer Immunotherapy-A Promising Strategy
JournalFrontiers in Immunology
PublisherFrontiers Media S.A.
MetadataShow full item record
AbstractSince the first reported spontaneous regression of tumors in patients with streptococcus infection, cancer biological therapy was born and it evolved into today's immunotherapy over the last century. Although the original strategy was unable to impart maximal therapeutic benefit at the beginning, it laid the foundations for the development of immune checkpoint blockade and CAR-T which are currently used for cancer treatment in the clinics. However, clinical applications have shown that current cancer immunotherapy can cause a series of adverse reactions and are captious for patients with preexisting autoimmune disorders. Salmonellae was first reported to exert antitumor effect in 1935. Until now, numerous studies have proved its potency as an antitumor agent in the near future. In this review, we summarize the currently available data on the antitumor effects of Salmonella, and discussed a possibility of integrating Salmonella into cancer immunotherapy to overcome current obstacles. Copyright 2021 Wang, Wei, Kalvakolanu, Guo and Zhang.
SponsorsLZ is supported by the National Natural Science Foundation of China (grant numbers 81773217), Research Fund of Jilin Provincial Science and Technology Department (grant numbers 20200404120YY and 20190701065GH), Jilin Province Health Technology Innovation Project (grant numbers 2019J030), the Fundamental Research Funds for the Central Universities, JLU and Chunhui international research project of Ministry of Education. DK is supported by the Cigarette Restitution Fund of the University of Maryland Greenebaum Cancer Center.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/15219
- Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
- Authors: Xie G, Cheng T, Lin J, Zhang L, Zheng J, Liu Y, Xie G, Wang B, Yuan Y
- Issue date: 2018 Sep 12
- The oncolytic virus ΔPK has multimodal anti-tumor activity.
- Authors: Aurelian L, Bollino D, Colunga A
- Issue date: 2016 Jul
- Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
- Authors: Guo Y, Chen Y, Liu X, Min JJ, Tan W, Zheng JH
- Issue date: 2020 Jan 28
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
- Authors: Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J
- Issue date: 2018
- Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
- Authors: Chon HJ, Lee WS, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, Kim JH, Kim C
- Issue date: 2019 Mar 1